These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 24862316)

  • 1. Nanotherapy for posterior eye diseases.
    Kaur IP; Kakkar S
    J Control Release; 2014 Nov; 193():100-12. PubMed ID: 24862316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
    Wang R; Gao Y; Liu A; Zhai G
    J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The suprachoroidal pathway: a new drug delivery route to the back of the eye.
    Rai Udo J; Young SA; Thrimawithana TR; Abdelkader H; Alani AW; Pierscionek B; Alany RG
    Drug Discov Today; 2015 Apr; 20(4):491-5. PubMed ID: 25448755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Potential of liposomes for the intravitreal injection of therapeutic molecules].
    Bochot A; Lajavardi L; Camelo S; Bourges JL; Behar-Cohen F; de Kozak Y; Fattal E
    Ann Pharm Fr; 2011 Mar; 69(2):100-7. PubMed ID: 21440102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug delivery to the posterior segment of the eye.
    Thrimawithana TR; Young S; Bunt CR; Green C; Alany RG
    Drug Discov Today; 2011 Mar; 16(5-6):270-7. PubMed ID: 21167306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of therapeutics for deep-seated ocular conditions - status quo.
    Nguyen H; Eng S; Ngo T; Dass CR
    J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular drug delivery: nanomedicine applications.
    Vandervoort J; Ludwig A
    Nanomedicine (Lond); 2007 Feb; 2(1):11-21. PubMed ID: 17716187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical drug delivery to retinal pigment epithelium with microfluidizer produced small liposomes.
    Lajunen T; Hisazumi K; Kanazawa T; Okada H; Seta Y; Yliperttula M; Urtti A; Takashima Y
    Eur J Pharm Sci; 2014 Oct; 62():23-32. PubMed ID: 24810393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
    Durgun ME; Güngör S; Özsoy Y
    J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ortho ester) nanoparticles targeted for chronic intraocular diseases: ocular safety and localization after intravitreal injection.
    Li H; Palamoor M; Jablonski MM
    Nanotoxicology; 2016 Oct; 10(8):1152-9. PubMed ID: 27108911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations.
    Loftsson T; Sigurdsson HH; Konrádsdóttir F; Gísladóttir S; Jansook P; Stefánsson E
    Pharmazie; 2008 Mar; 63(3):171-9. PubMed ID: 18444504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomes for intravitreal drug delivery: a state of the art.
    Bochot A; Fattal E
    J Control Release; 2012 Jul; 161(2):628-34. PubMed ID: 22289436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug delivery to the posterior segment of the eye.
    Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
    Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in ocular drug delivery.
    Rawas-Qalaji M; Williams CA
    Curr Eye Res; 2012 May; 37(5):345-56. PubMed ID: 22510004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on "Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo Using Annexin A5-Associated Liposomes": Topical Liposomal Bevacizumab Results in Negligible Retinal Concentrations.
    Urtti A
    Small; 2019 Apr; 15(15):e1805199. PubMed ID: 30977598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases.
    Arranz-Romera A; Esteban-Pérez S; Garcia-Herranz D; Aragón-Navas A; Bravo-Osuna I; Herrero-Vanrell R
    Drug Discov Today; 2019 Aug; 24(8):1644-1653. PubMed ID: 30928691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye.
    Fangueiro JF; Veiga F; Silva AM; Souto EB
    Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.
    Short BG
    Toxicol Pathol; 2008 Jan; 36(1):49-62. PubMed ID: 18337221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.